This study compared insulin degludec/liraglutide (IDegLira) to standard insulin in patients with uncontrolled Type 2 diabetes (T2D).  The authors concluded that IDegLira improved patient compliance to treatment and reduced treatment-related stress compared to conventional insulin.

This review examined the effect of aerobic exercise on fatigue in rheumatoid arthritis patients. 

This study examined whether sotagliflozin (Zynquista) helped improve kidney function in patients with Type 1 diabetes (T1D). The authors concluded that sotagliflozin improved several factors of kidney function.

This study looked at the effect of inflammation on the development of chronic kidney disease in patients with rheumatoid arthritis. The authors concluded that patients with persistent inflammation are at a higher risk of developing chronic kidney disease. 

This study explored the influence of other diseases on disease activity in rheumatoid arthritis (RA) patients. The study concluded that cardiovascular (heart and blood vessel) diseases were strongly related to disease activity.

This study examined if nutritional supplements can reduce the rate of hypoglycemia in patients with Type 2 diabetes (T2D). This study concluded that these supplements helped reduce hypoglycemia and lowered mortality risk for these patients.

This study is comparing the effectiveness of two types of insulin when they are given using an automated insulin pump to patients with type 1 diabetes (T1D). The main outcome will be to examine patients’ blood glucose levels after 6 weeks. This study is recruiting in Austin, TX, US.

This study investigated the safety and effectiveness of BCD-055 (BCD), a biosimilar of infliximab (IFX; Remicade).

They found that the safety and effectiveness of BCD were similar to IFX. 

This study wanted to compare how well two different kinds of insulin, insulin glargine (Lantus) 300u/ml, and insulin degludec (Tresiba), worked for people with type 2 diabetes. The study found that the patients in both groups had similar blood glucose control and similar episodes of low blood glucose events. 

This study is comparing the effectiveness of two different doses of semaglutide (Ozempic) in patients with Type 2 diabetes (T2D). The main outcome to be measured will be the change in HbA1c (average blood glucose levels over 3 months).